Premium
Disease‐Associated Changes in Drug Transporters May Impact the Pharmacokinetics and/or Toxicity of Drugs: A White Paper From the International Transporter Consortium
Author(s) -
Evers Raymond,
PiquetteMiller Micheline,
Polli Joseph W.,
Russel Frans G.M.,
Sprowl Jason A.,
Tohyama Kimio,
Ware Joseph A.,
Wildt Saskia N.,
Xie Wen,
Brouwer Kim L.R.
Publication year - 2018
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt.1115
Subject(s) - adme , transporter , pharmacokinetics , pharmacology , drug , disease , toxicity , drug development , distribution (mathematics) , medicine , drug metabolism , biology , genetics , gene , mathematical analysis , mathematics
Drug transporters are critically important for the absorption, distribution, metabolism, and excretion (ADME) of many drugs and endogenous compounds. Therefore, disruption of these pathways by inhibition, induction, genetic polymorphisms, or disease can have profound effects on overall physiology, drug pharmacokinetics, drug efficacy, and toxicity. This white paper provides a review of changes in transporter function associated with acute and chronic disease states, describes regulatory pathways affecting transporter expression, and identifies opportunities to advance the field.